Dermatology Times, April 2021 (Vol. 42, No. 4)

Emerging Agents Augment Melasma Modalities

April 09, 2021

An array of agents for blocking visible light and lightening skin are joining the armamentarium to treat melasma. Despite this expanding number of therapeutic interventions, melasma is a chronic, therapeutically challenging disease for which there is no cure, so treatment plans should address both management of the disease and patient expectations.

Vaccine Patients Experiencing ‘Vaccine Arm’ Days After Injection

March 19, 2021

Increasing reports have surfaced of vaccine recipients experiencing delayed cutaneous side effects after receiving the first dose. Experts assure that while the delayed side effect is uncomfortable, it is temporary and can be treated at home.

Ruxolitinib Cream NDA Accepted for Priority Review by FDA

March 12, 2021

Incyte announces the FDA has accepted the NDA for ruxolitinib cream for priority review. Ruxolitinib cream is a topical selective janus kinase (JAK)1/JAK2 inhibitor intended for the treatment of atopic dermatitis.